Thymosin alpha-1 and KPV are both discussed under immune support, which is why they are compared. Thymosin alpha-1 is a peptide studied for enhancing T-cell and natural killer cell activity. KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) studied for reducing inflammation. Neither is FDA-approved.
At a glance
| Thymosin alpha-1 | KPV | |
|---|---|---|
| What it is | Immune-modulating peptide studied for T-cell and natural killer cell function, including in chronic viral hepatitis | Tripeptide (lysine-proline-valine) from the end of alpha-MSH, studied for anti-inflammatory activity in the gut and skin |
| How it's thought to work | Studied for T-cell maturation, NK cell activity, cytokine modulation and dendritic cell function | Studied for entering cells and reducing NF-kB inflammatory signaling, without the pigmentation activity of full alpha-MSH |
| Regulatory status | Not FDA-approved; reported to be approved in some countries outside the US. A 2024 FDA review found insufficient evidence of effectiveness | Not FDA-approved for any human use; sold only as a research chemical |
| Strength of evidence | Randomized human trials with mixed results, such as one in chronic hepatitis C combined with interferon | Preclinical (animal and lab) studies in colitis and skin inflammation; human clinical data is limited |
| Reported side effects | Rare injection site reactions | Minimal; occasional injection site irritation. Long-term human safety data is limited |
| Common vial sizes | 1.6mg, 3.2mg | 5mg, 10mg |
| Mixing math example | 3.2 mg + 1 mL BAC water = 3,200 mcg/mL, 32 mcg per unit | 5 mg + 1 mL BAC water = 5,000 mcg/mL, 50 mcg per unit |
Key differences
Thymosin alpha-1 is studied for supporting immune activity: T-cell maturation, natural killer cell activity, cytokine modulation and dendritic cell function. KPV is studied for the opposite direction of inflammation, reducing pro-inflammatory NF-kB signaling inside cells, with research concentrated on the gut and skin.
Thymosin alpha-1 is reported to be approved in some countries outside the United States, but a 2024 FDA review found insufficient evidence of effectiveness for the uses it evaluated. KPV is sold only as a research chemical.
Thymosin alpha-1's reported side effects are rare injection site reactions. KPV's are minimal, mainly occasional injection site irritation, and its long-term human safety data is limited.
What the research covers
Thymosin alpha-1 has randomized human trials, including in chronic hepatitis C, with mixed results. KPV's findings come from animal models of colitis and skin inflammation, and human clinical data is limited.
Sources
- Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Sherman KE et al. Hepatology, 1998. Human trial
- Thymosin alpha1: the regulator of regulators?. Pierluigi B et al. Annals of the New York Academy of Sciences, 2010. Review
- Thymosin Alpha-1 (Ta1) Related Bulk Drug Substances (Pharmacy Compounding Advisory Committee briefing). U.S. Food and Drug Administration, 2024. Regulatory document
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Kannengiesser K et al. Inflammatory Bowel Diseases, 2008. Preclinical
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Dalmasso G et al. Gastroenterology, 2008. Preclinical
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Getting SJ et al. Journal of Pharmacology and Experimental Therapeutics, 2003. Preclinical
Frequently asked questions
What is the difference between thymosin alpha-1 and KPV?
Thymosin alpha-1 is studied for enhancing T-cell and natural killer cell function. KPV is a fragment of alpha-MSH studied for reducing inflammatory signaling in the gut and skin.
Is thymosin alpha-1 or KPV FDA-approved?
Neither is FDA-approved. Thymosin alpha-1 is reported to be approved in some other countries, and KPV is sold only as a research chemical.
Which has more human research, thymosin alpha-1 or KPV?
Thymosin alpha-1 has randomized human trials, with mixed results. KPV's research is mainly in animal models.
Are thymosin alpha-1 and KPV related?
No. Thymosin alpha-1 and KPV are unrelated peptides; KPV is derived from alpha-MSH.
Both entries, plus the calculator
The PeptidesAI app covers Thymosin alpha-1, KPV and 68 other compounds, with a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store